Literature DB >> 24428389

Different subsets of natural killer T cells may vary in their roles in health and disease.

Vipin Kumar1, Terry L Delovitch.   

Abstract

Natural killer T cells (NKT) can regulate innate and adaptive immune responses. Type I and type II NKT cell subsets recognize different lipid antigens presented by CD1d, an MHC class-I-like molecule. Most type I NKT cells express a semi-invariant T-cell receptor (TCR), but a major subset of type II NKT cells reactive to a self antigen sulphatide use an oligoclonal TCR. Whereas TCR-α dominates CD1d-lipid recognition by type I NKT cells, TCR-α and TCR-β contribute equally to CD1d-lipid recognition by type II NKT cells. These variable modes of NKT cell recognition of lipid-CD1d complexes activate a host of cytokine-dependent responses that can either exacerbate or protect from disease. Recent studies of chronic inflammatory and autoimmune diseases have led to a hypothesis that: (i) although type I NKT cells can promote pathogenic and regulatory responses, they are more frequently pathogenic, and (ii) type II NKT cells are predominantly inhibitory and protective from such responses and diseases. This review focuses on a further test of this hypothesis by the use of recently developed techniques, intravital imaging and mass cytometry, to analyse the molecular and cellular dynamics of type I and type II NKT cell antigen-presenting cell motility, interaction, activation and immunoregulation that promote immune responses leading to health versus disease outcomes.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD1; T-cell receptor; antigen-presenting cells; cytokines; dendritic cells; glycolipids; innate immunity; myeloid-derived suppressor cells; natural killer T cells; sulphatide

Mesh:

Year:  2014        PMID: 24428389      PMCID: PMC4080948          DOI: 10.1111/imm.12247

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  136 in total

Review 1.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

Review 2.  Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.

Authors:  Victoria Lawson
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

Review 3.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

Review 4.  Imaging natural killer T cells in action.

Authors:  Connie H Y Wong; Paul Kubes
Journal:  Immunol Cell Biol       Date:  2013-02-05       Impact factor: 5.126

5.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

6.  Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice.

Authors:  Claire Forestier; Alberto Molano; Jin Seon Im; Yves Dutronc; Betty Diamond; Anne Davidson; Petr A Illarionov; Gurdyal S Besra; Steven A Porcelli
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

7.  Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor.

Authors:  Onisha Patel; Daniel G Pellicci; Stephanie Gras; Maria L Sandoval-Romero; Adam P Uldrich; Thierry Mallevaey; Andrew J Clarke; Jérôme Le Nours; Alex Theodossis; Susanna L Cardell; Laurent Gapin; Dale I Godfrey; Jamie Rossjohn
Journal:  Nat Immunol       Date:  2012-07-22       Impact factor: 25.606

8.  The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice.

Authors:  Avneesh K Singh; Jun-Qi Yang; Vrajesh V Parekh; Jie Wei; Chyung-Ru Wang; Sebastian Joyce; Ram R Singh; Luc Van Kaer
Journal:  Eur J Immunol       Date:  2005-04       Impact factor: 5.532

9.  Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice.

Authors:  Lennart T Mars; Véronique Laloux; Karine Goude; Sabine Desbois; Abdelhadi Saoudi; Luc Van Kaer; Hans Lassmann; André Herbelin; Agnès Lehuen; Roland S Liblau
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

10.  Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells.

Authors:  Nadine Y Crowe; Adam P Uldrich; Konstantinos Kyparissoudis; Kirsten J L Hammond; Yoshihiro Hayakawa; Stephané Sidobre; Rachael Keating; Mitchell Kronenberg; Mark J Smyth; Dale I Godfrey
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

View more
  46 in total

1.  Targeted disruption of CD1d prevents NKT cell development in pigs.

Authors:  Guan Yang; Bianca L Artiaga; Timothy J Hackmann; Melissa S Samuel; Eric M Walters; Shahram Salek-Ardakani; John P Driver
Journal:  Mamm Genome       Date:  2015-05-01       Impact factor: 2.957

2.  Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease.

Authors:  Igor Maricic; Enrico Girardi; Dirk M Zajonc; Vipin Kumar
Journal:  J Immunol       Date:  2014-09-26       Impact factor: 5.422

Review 3.  Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Luc Van Kaer; Lan Wu; Vrajesh V Parekh
Journal:  Immunology       Date:  2015-06-22       Impact factor: 7.397

Review 4.  Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset.

Authors:  Suryasarathi Dasgupta; Vipin Kumar
Journal:  Immunogenetics       Date:  2016-07-12       Impact factor: 2.846

5.  Inhibition of CD1d-mediated antigen presentation by the transforming growth factor-β/Smad signalling pathway.

Authors:  Jennifer C Bailey; Abhirami K Iyer; Gourapura J Renukaradhya; Yinling Lin; Hoa Nguyen; Randy R Brutkiewicz
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

6.  α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.

Authors:  Vanessa Sainz; Liane I F Moura; Carina Peres; Ana I Matos; Ana S Viana; Angela M Wagner; Julia E Vela Ramirez; Teresa S Barata; Manuela Gaspar; Steve Brocchini; Mire Zloh; Nicholas A Peppas; Ronit Satchi-Fainaro; Helena F Florindo
Journal:  Acta Biomater       Date:  2018-06-22       Impact factor: 8.947

Review 7.  What rheumatologists need to know about innate lymphocytes.

Authors:  Mark A Exley; George C Tsokos; Kingston H G Mills; Dirk Elewaut; Ben Mulhearn
Journal:  Nat Rev Rheumatol       Date:  2016-09-02       Impact factor: 20.543

8.  Differential dependence on nuclear factor-κB-inducing kinase among natural killer T-cell subsets in their development.

Authors:  Haruka Noma; Koji Eshima; Masashi Satoh; Kazuya Iwabuchi
Journal:  Immunology       Date:  2015-06-25       Impact factor: 7.397

Review 9.  Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE.

Authors:  Luc Van Kaer; Joshua L Postoak; Chuan Wang; Guan Yang; Lan Wu
Journal:  Cell Mol Immunol       Date:  2019-03-15       Impact factor: 11.530

Review 10.  Mechanisms and Consequences of Antigen Presentation by CD1.

Authors:  Luc Van Kaer; Lan Wu; Sebastian Joyce
Journal:  Trends Immunol       Date:  2016-09-09       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.